St. Alphonsus Health System
Print    Email
Decrease (-) Restore Default Increase (+)

Research Opportunities

Title   Phosphodiesterase Type 5 Inhibition with Tadalafil Changes Outcomes in Heart Failure (PITCH-HF)
Description   Randomized, double blind, Placebo controlled trial to determine the safety, efficacy and effect of Tadalafil (Cialis) on the functional capacity/Quality of Life for patients with left ventricular systolic dysfunction (LVSD), heart failure (HF) and secondary pulmonary hypertension (PH).

This study is sponsored by Massachusetts General Hospital (MGH) and New England Research Institutes, Inc (NERI) grant award from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH).
IRB Number   13-24
Treatment   Cardiovascular
Inclusion/Notes  

Male or female over 21 years of age with LVSD HF and secondary PH. To learn more about Cardiovascular research, click here.

Start Date   01/01/2014
Principal Name   Steven Fonken, MD and J. Antonio G. Lopez, MD
Contact Name   Kelly Beltz or Christine Shirazi
Fax   (208) 367-2830
Current Trial Type   Randomized, double blind, placebo-controlled
Phone   (208) 367-8880

©

 2014  

Saint Alphonsus Health System  |  1055 North Curtis Road  Boise, ID 83706  |  208-367-2121

   Facebook       Twitter       YouTube